Table 2.
Multivariable Analysis of Community Health Status and Transplant Outcomes in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation
| Population | Outcome | Variable | HR (99% CI) | p-value |
|---|---|---|---|---|
| All patients (n=18,544) | Overall mortality | PCS | 1.04 (1.00 – 1.08) | 0.0089 |
| CCS | 1.01 (0.98 – 1.04) | 0.5379 | ||
| Patients with hematologic malignancies (n=17,793) | Overall mortality | PCS | 1.04 (1.00 – 1.08) | 0.0102 |
| CCS | 1.01 (0.97 – 1.04) | 0.6658 | ||
| Relapse | PCS | 0.97 (0.94 – 1.01) | 0.0441 | |
| CCS | 1.00 (0.96 – 1.04) | 0.9310 | ||
| Non-relapse mortality | PCS | 1.08 (1.02 – 1.15) | 0.0004 | |
| CCS | 1.02 (0.97 – 1.07) | 0.3106 |
CCS = center community-risk sore; PCS= patient community-risk score.
Hazard ratio (HR) quantifies risk change corresponding to one standard deviation increase in continuous covariate.
Bolded variables indicate a significant association defined by p≤0.01. All models included the following significant co-variables: diagnosis, disease status/ stage, donor type, HCT-comorbidity index, HLA matching, recipient age, donor age for unrelated BM or PBSC donors, recipient and donor gender, recipient and donor CMV serologies, recipient’s self-reported race and ethnicity, donor race, donor ethnicity, donor parity, recipient’s performance status score at transplant, prior autologous transplant, resistant disease in lymphoma only, NHL subtype, time from diagnosis to transplant for AML or ALL not in CR1 or PIF, AML transformed from MDS or MPN disease, therapy related AML or MDS, AML ELN risk group, number of induction cycles to achieve latest CR before HCT for AML and ALL patients, year of transplant, T-cell lineage in ALL, Philadelphia chromosome in ALL, ALL cytogenetic risk group, ALL molecular marker (BR/ABL at any time between diagnosis and HCT), MDS with predisposing conditions, MDS IPSS-R prognostic risk category/ score at HCT, deletion 17p in CLL, MM cytogenetics risk group, MM ISS at diagnosis, plasma cell disorder disease status at HCT, plasma cell leukemia, history of mechanical ventilation, history of invasive fungal infection, and median household income based on ZIP Code of residence of recipient.